 Presentación
IVTIP members are genuinely interested in the use of in vitro testing for regulatory/safety testing or early decision-making in compound discovery and development. IVTIP members endorse “The 21st Century Toxicity Testing’’ strategy as the ultimate replacement of animal experimentation for regulatory/safety testing. IVTIP members are supportive of the 3Rs: applying opportunities resulting in reduction of animal numbers or refinement of existing animal experiments contributing to the development of replacement strategies. They also endorse a 4th R: responsibility towards animals as well as towards the growing demand by society for better ways of assuring safety.
This meeting is focused on in vitro toxicology methods for the assessment of nanomaterials. |
|
Programa
08.30 – 08.45 h Welcome
Bart De Wever, ALTEXA Development, Monaco
IVTIP Board/Executive Secretary
08.45 – 09.30 h Quality assessment of toxicity studies on nanomaterials
Jeffrey W. Card, Senior Program Manager, Toxicology Intertek Cantox, Ontario, Canada
09.30 – 10.15 h Nanomaterial measurement: the role of standardization and harmonization
Christoph Klein, Program Manager
Institute for Reference Materials and Measurements
JRC, European Commission, Belgium
10.15 – 10.45 h Coffee Break
10.45 – 11.30 h Experimental nanotoxicity testing in vivo and in vitro
Frieke Kuper, Senior Scientist Quality of Life
TNO, The Netherlands
11.30 – 12.15 h Regulatory issues and nanomaterial riks
Steffi Friedrich, Director General
The Nanotechnology Industry Association, Belgium
12.15 - 13.30 h Lunch
13.30 – 14.15 h In vitro models of biological barriers for safety and efficacy testing of
nanomedicines
Claus-Michael Lehr, Head, Department of Drug Delivery
Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Germany
14.15 – 15.00 h The in vivo fate of nanomedicines and nanotoxicity
Elias Fattal, Director UMR CNRS 8612.
Univ. Of Paris Sud, School of Pharmacy, France
15.00 – 15.30 h Coffee Break
15.30 – 16.10 h Advances and challenges when investigating toxicological responses to
inhaled nanoparticles at the in vitro level
Tobias Stoeger, Head Institute of Inhalation Biology
Helmholtz Zentrum München, Germany
16.10 – 16.30 h Human skin organ culture as a potential non animal model for safety
evaluation of metallic nanoparticles
Myriam Oron, R&D Manager of Clineral, Chemist of the Medical Division
AHAVA Dead Sea Laboratories, Israel
16.30 – 16.50 h New advances in the toxicological evaluation of nanomaterials
Blanca Suarez, Head of Biomedicine Unit
Gaiker Technology Center, Spain
16.50 – 17.35 h Presentation of 3 selected posters
17.35 – 18.00 h Round Table Round up
Fecha
19 de Abril de 2012
Lugar de celebración
GAIKER-IK4
Parque Tecnológico, Ed. 202
48170 Zamudio (Bizkaia)
Hora: 8:30-18:00
Cuota:
Industry: 250€
Academia: 150€
Students: 50€
Inscripciones: